0
0
0
0
1
2
3
$0
Is Edwards Lifesciences solid or fragile? The Finex Financial Health Scanner reads EW's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $6.1B |
|---|---|
| Net income | $1.1B |
| Operating margin | 20.8% |
| Net margin | 17.7% |
| Cash and investments | $4.2B |
| Total debt | $598.3M |
| Free cash flow | $1.1B |
| Revenue growth (1 year) | 11.5% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.